What is the domestic market price of tucatinib? Price comparison of different versions

The situation of Tucatinib in the domestic market is relatively complicated, mainly because its original drug has not yet been officially launched in China, so patients cannot obtain the drug through the domestic medical insurance system. The original drug of tucatinib is produced by Seattle Genetics. The specification is 150mg*84 tablets per box. Due to its high research and development costs and market positioning, the price of the original drug in the European market can be as high as more than 40,000 yuan. This price is undoubtedly a huge burden for most patients, especially when the drug is not covered by medical insurance, the patient's treatment cost will be very high.

In contrast, generic drugs of tucatinib have appeared in some international markets, especially those produced by Laos pharmaceutical factories. The specifications are 150mg*60 tablets, and each box sells for about more than 2,000 yuan. This price is much more affordable than the original drug, significantly reducing the treatment cost for patients. Although there is a huge price difference, generic drugs are similar to the original drugs in terms of ingredients and therapeutic effects. Therefore, many patients choose to use generic drugs to replace the original drugs. Especially when it comes to the affordability of drugs, generic drugs provide a relatively economical option.

It is worth noting that although the price of generic drugs is significantly lower than that of original drugs, patients still need to discuss with their doctors when choosing to use them to ensure the effectiveness and safety of the treatment plan. While the quality of generic medicines is regulated and approved, some patients may have individual differences in efficacy or tolerability, so physician advice remains critical. The launch of generic drugs has expanded the therapeutic scope of tucatinib, providing a feasible treatment option for patients with limited financial conditions.

Although the original drug of tucatinib has not yet been officially launched in the domestic market, as the demand in the international market continues to grow and the availability of generic drugs increases, more internationally imported drugs may enter the Chinese market in the future. Patients can choose suitable drugs through reasonable channels to ensure a balance between economic conditions and treatment effects and improve the sustainability of treatment.

Reference materials:https://www.tukysa.com/